<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Department of Medicine

School of Medicine

Home News Stop the Start: Therapeutics Targeting C5aR1 to Treat Early Rheumatoid Arthritis as a New Pathway to Precision Medicine back to News

Stop the Start: Therapeutics Targeting C5aR1 to Treat Early Rheumatoid Arthritis as a New Pathway to Precision Medicine

Nirmal K. Banda, PhD, MPhil, MS

Written by Department of Medicine on October 11, 2022

Watch the Department of Medicine's Oct. 11, 2022 Research & Innovation Conference – "Stop the Start: Therapeutics Targeting C5aR1 to Treat Early Rheumatoid Arthritis as a New Pathway to Precision Medicine" with Nirmal K. Banda, PhD, MPhil, MS, research professor in the Division of Rheumatology.

 

Topics: Research

Department of Medicine

Divisions

Residency and Fellowship Programs

Grand Rounds

Newsroom

Contact Us

School

School of Medicine

Apply Now

Alumni

Directories

Find a Doctor

Find a Researcher

Find a Faculty Member

Affiliate/Partner Hospitals

Maps and Parking

Give

Donate

CU Foundation

© 2024  The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.